Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.Business Wire • Wednesday
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)Business Wire • Monday
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026Business Wire • 10/13/26
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/26
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026Business Wire • 08/10/26
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?Zacks Investment Research • 06/24/26
Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C VirusBusiness Wire • 06/23/26
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)Business Wire • 06/18/26
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceBusiness Wire • 05/28/26
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/26
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026Business Wire • 05/11/26
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?Zacks Investment Research • 05/07/26
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026Business Wire • 05/04/26
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaBusiness Wire • 04/13/26
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026Business Wire • 04/07/26
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)Business Wire • 03/30/26
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual MeetingBusiness Wire • 02/10/26
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 02/09/26
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025Business Wire • 02/09/26
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 OutlookBusiness Wire • 01/08/26
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/26